# (-)-ALPHA-BISABOLOL (alpha-bisabolol) — Global Cosmetic Regulatory & Formulation Monograph

- **Canonical URL**: https://www.inciname.com/en/ingredients/alpha-bisabolol
- **Standard INCI**: `(-)-ALPHA-BISABOLOL`
- **KR MFDS Standard Name**: `알파-비사보롤`
- **CAS No.**: `23089-26-1`
- **EC / EINECS No.**: `245-423-3`
- **Origin**: `plant`
- **Functions**: 피부컨디셔닝제
- **Molecular Formula / MW**: `C15H26O` (222.37 g/mol)

## 1. 7-Track Official Regulatory Label Names
| Track | Official Label Nomenclature |
| :--- | :--- |
| KR (MFDS Standard) | 알파-비사보롤 |
| KR (Former Names) | — |
| EU (CosIng 1223/2009) | (-)-ALPHA-BISABOLOL |
| US (PCPC / MoCRA INCI) | (-)-ALPHA-BISABOLOL |
| US (FDA OTC Monograph) | — |
| CN (NMPA IECIC) | — |
| JP (JCIA / MHLW QD) | (-)-ALPHA-BISABOLOL  |

## 2. Layer 1 — Global 6-Region Statutory Summary
- **KR (MFDS)**: `noted`
- **EU (1223/2009)**: `none`
- **US (FDA/MoCRA)**: `none`
- **CN (NMPA IECIC)**: `none` (Entry: `—`)
- **JP (MHLW)**: `none`
- **ASEAN (ACD)**: `none`



## 3. Layer 2 — Toxicological & Historical Safe Use Concentrations
- **cn_iecic_max** (leave_on): ≤ 2% — NMPA IECIC (2025) Entry 05618 (2025)
- **cn_iecic_max** (rinse_off): ≤ 1% — NMPA IECIC (2025) Entry 05618 (2025)

## 4. Layer 3 — Formulation Quartiles & Compatibility
- **Optimal pH Window**: 3.5 – 9
- **Max Process Temp**: ≤ 75°C
- **Synergy Pairings**: NIACINAMIDE, ALPHA-ARBUTIN, RETINOL, PANTHENOL
- **Incompatibilities**: For KR MFDS brightening functional claim (0.5%), must specifically use (-)-Alpha-Bisabolol meeting optical rotation purity standards rather than racemic Bisabolol

## 5. Academic Monograph
■ [1. Chemical Identity & International Labeling Nomenclature]
  - INCI Name: (-)-ALPHA-BISABOLOL | CAS No.: 23089-26-1 | EC No.: 245-423-3
  - Origin: PLANT | Functions: SKIN CONDITIONING
  - Physicochemical Profile: Formula C15H26O | MW 222.37 g/mol | LogP 3.79 | Ionic Nature: non-ionic | PubChem CID 442343
  - Official Regional Label Names: US [(-)-ALPHA-BISABOLOL] · EU [(-)-ALPHA-BISABOLOL] · CN [-] · JP [-] · JP Quasi-Drug [-]
■ [2. Dermatological Mechanism of Action & Functional Role]
  - Enantiomerically pure levorotatory isomer ((-)-alpha-Bisabolol, CAS 23089-26-1), strictly distinguished from racemic Bisabolol (CAS 515-69-5). Exhibits approximately twice the anti-inflammatory bioactivity of the racemate via COX-2/iNOS inhibition and cAMP-mediated melanogenesis attenuation.
■ [3. Global 6-Jurisdiction Regulatory Status & Safety Limits (Layer 1 & Layer 2)]
  - Regional Summary: KR: NOTED | EU: NONE | US: NONE | CN: NONE | JP: NONE | ASEAN: NONE (CN IECIC (2025) Entry No. Unlisted (-))
  - [KR / CLAIM / noted]: 
  - Official Safety & Historical Use Concentration (Layer 2): CN_IECIC_2025 (cn_iecic_max, leave_on): Max 2.0% / CN_IECIC_2025 (cn_iecic_max, rinse_off): Max 1.0%
■ [4. Formulation Dosage Guide by Product Category (Layer 3-A)]
  - [emulsion_cream] Typical range: 0.1 ~ 1.0% (Median 0.5%, Ref: MFDS Functional Cosmetics Notice Annex 4 (0.5%) & CIR Bisabolol Assessment) — KR MFDS Brightening Functional Active (0.5%) & potent anti-inflammatory enantiomer
■ [5. Formulation Engineering, Stability & Incompatibility Matrix (Layer 3-B)]
  - Addition Phase: Cool-down Phase (< 60°C) or Oil Phase
  - Optimal pH Range: pH 3.5 ~ 9.0 | Max Process Temp: Max 75°C | Electrolyte Tolerance: HIGH
  - Incompatibility / Caution: For KR MFDS brightening functional claim (0.5%), must specifically use (-)-Alpha-Bisabolol meeting optical rotation purity standards rather than racemic Bisabolol
  - Synergy Pairings: NIACINAMIDE, ALPHA-ARBUTIN, RETINOL, PANTHENOL | Reference Trade Names: Candeia Natural (-)-Alpha-Bisabolol
■ [6. Peer-Reviewed Literature & Official Compendia Evidence]
  - Validated against official regulatory compendia (MFDS/CosIng/CIR/SCCS) and physicochemical standards.

## 6. Linked PubMed Literature